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Effects of non-sedative anxiolytic drugs on responses
to GABA and on diazepam-induced enhancement of
these responses on mouse neurones in cell culture
1Peter P. De Deyn & 2Robert L. Macdonald
University of Michigan, Neuroscience Laboratory Building, 1103 East Huron Street, Ann Arbor, Michigan,
48104, U.S.A.
1 Intracellular microelectrode recording techniques were performed on mouse spinal cord and
cerebral hemisphere neurones grown in primary dissociated cell culture. The effects of several anx-
iolytics applied by local pressure ejection on responses to y-aminobutyric acid (GABA) evoked by
iontophoresis were investigated. Responses to GABA were depolarizing since intracellular chloride
ion concentration was increased by injection from potassium chloride (3 M)-filled recording micro-
pipettes and neurones were held at large negative membrane potentials (-70 to -90mV). The
agents studied were six 'non-sedative anxiolytics', CL 218,872 (3-methyl-6-(3-trifluoromethyl-phenyl)
1,2,4-triazolo(4,3-b) pyridazine), PK 8165 (2-phenyl-442-(4-piperidinyl)ethyl)-quinoline), PK 9084 (2-
phenyl-442-(3-piperidinyl)ethyl)-quinoline), CGS 9896 (2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-
c)quinoline-3(3H)-one), ZK 91296 (ethyl 5-benzyloxy-4-methoxymethyl-f-carboline-3-#-carboxylate),
buspirone (8-4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl-8-azaspiro[4.5]decane-7,9-dione), and two
sedative anxiolytics, diazepam and zopiclone ([6-5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5 H-
pyrrolo [3,4-b] pyrazin-5-yl] 4-methyl-1-piperazinecarboxylate).
2 Direct effects on responses to GABA were studied for all drugs applied in varying concentra-
tions. For the drugs which significantly altered responses to GABA, the effects of the benzodiaze-
pine receptor antagonists Ro 15-1788 (ethyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo4H-imidazo(1,5a)
(1,4)benzodiazepine-3-carboxylate) and CGS 8216 (2-phenylpyrazolo(4,3-c)-quinolin-3(5H-one)
were evaluated. For the drugs devoid of significant direct effect on responses to GABA, the influ-
ence on diazepam-induced enhancement of responses to GABA was evaluated.
3 Diazepam, zopiclone and CL 218,872 concentration-dependently and reversibly enhanced
responses to GABA. Maximal enhancement was 82% for diazepam (500nM), 64% for zopiclone
(1OMm) and 20% for CL 218,872 (10pM). PK 8165 effects varied with concentration, enhancing
responses to GABA (up to 18%) at nm concentrations and reducing responses to GABA (up to
90%) at ym concentrations. CGS 9896, ZK 91296, PK 9084 and buspirone, in concentrations
ranging from 1 nm to 10 ym, lacked significant direct effects on responses to GABA.
4 The enhancing effects of diazepam, zopiclone, CL 218,872 and PK 8165 were antagonized by Ro
15-1788. However, the reducing effect on responses to GABA of PK 8165 at ym concentrations was
not antagonized by CGS 8216. CGS 9896 and ZK 91296 concentration-dependently blocked the
diazepam-induced enhancement of responses to GABA. However, PK 9084 and buspirone did not
antagonize the diazepam-induced enhancement of responses to GABA.
5 These results indicate that diazepam and zopiclone may be full agonists, CL 218,872 and PK
8165 are partial agonists, and CGS 9896 and ZK 91296 are pure antagonists at benzodiazepine
receptors. On the other hand, PK 9084 and buspirone do not interact with benzodiazepine recep-
tors.
1 Present address: Born Bunge Foundation, U.I.A., Laboratory of Neurochemistry, Universiteitsplein 1, 2610 Wilrijk Ant-
werpen, Belgium.
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Introduction
The benzodiazepines, in addition to their anxiolytic
and anticonvulsant properties, have sedative effects
(Fink & Swinyard, 1962; Haefely et al., 1981), and
the use of these drugs is associated with the develop-
ment of tolerance and dependence (Allgulander,
1978). As a result there has been a continuing effort
to develop selective, non-sedative anxiolytic drugs.
Several benzodiazepine receptor ligands and non-
benzodiazepine receptor ligands have been proposed
in this respect. Some of these compounds have been
suggested to be devoid of induction of tolerance
and/or dependence (Lamb & Griffiths, 1984; Ger-
hardt et al., 1985).
Six novel compounds, suggested to be anxiolytic
drugs, are considered in this study: CL 218,872 (3-
methyl-6-(3-trifluoromethylphenyl)1,2,4-triazolo(4,-3-
b) pyridazine), PK 8165 (2-phenyl4-(2(4-piperidinyl)
ethyl)-quinoline), PK 9084 (2-phenyl-4-(243-piperi-
dinyl)ethyl)-quinoline), CGS 9896 (2-(4-chlorophenyl)-
2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one), ZK
91296 (ethyl 5-benzyloxy-4-methoxymethyl-p-
carboline-3-f-carboxylate) and buspirone (8-4-[4-(2-
pyrimidinyl ) - 1 - piperazinyl ] butyl - 8 - azaspiro [4.5]
decane-7,9-dione). All of these compounds have been
demonstrated to display a non-sedative anxiolytic
behavioural profile. CL 218,872 was shown to be a
central benzodiazepine receptor ligand (Squires et
al., 1979; Lippa et al., 1979ab). This tri-
azolopyridazine was found to be relatively free of
ataxic and depressant side-effects, to increase pun-
ished responding in a conflict procedure and to
protect against pentylenetetrazol-induced seizures
(Squires et al., 1979; Lippa et al., 1979b). However,
the initial results indicating that CL 218,872 is non-
sedative have not been confirmed (Oakley et al.,
1984; File et al., 1985; McElroy et al., 1985). PK
8165 and PK 9084 are both phenylquinolines and
were found to have a non-sedative anxiolytic profile
(Le Fur et al., 1981). However, subsequent investiga-
tors have failed to substantiate that the phenylquin-
olines are non-sedative (File & Lister, 1983; File,
1983; Keane et al., 1984). Both phenylquinolines
have been suggested to be partial agonists at the
benzodiazepine receptor (Morelli et al., 1982; Gee et
al., 1983; Benavides et al., 1984). CGS 9896, a pyra-
zoloquinoline, (Yokoyama et al., 1982) and ZK
91296, a fl-carboline, (Petersen et al., 1984; Pellow &
File, 1986) were shown to be non-sedative anx-
iolytics and to protect against pentylenetetrazol-
induced seizures. Both CGS 9896 (Yokoyama et al.,
1982; Gee & Yamamura, 1982) and ZK 91296
(Petersen et al., 1984) are known to be benzodiaze-
pine receptor ligands. Buspirone, a piperazinyl
pyrimidine, is a non-benzodiazepine receptor ligand
with anticonflict activity (Riblet et al., 1982; Geller &
Hartmann, 1982). Several clinical trials have con-
firmed the non-sedative anxiolytic profile of this
compound (Goldberg & Finnerty, 1979; Rickels et
al., 1982; Newton et al., 1982).
Diazepam and zopiclone ([6-(5-chloro-2-pyridyl-
6,7-dihydro-7-oxo-5 H-pyrrolo [3,4-b] pyrazine-5-
yl] 4-methyl-1-piperazinecarboxylate) were included
as sedative anxiolytic drugs. Diazepam is a benzo-
diazepine receptor agonist (Haefely et al., 1981), dis-
playing all benzodiazepine-like activities, i.e.,
anxiolytic, anticonvulsant, sedative and muscle relax-
ant effects. The pyrrolopyrazine zopiclone, believed
to be a benzodiazepine receptor ligand (Blanchard et
al., 1979; 1983), has a similar benzodiazepine-like
pharmacological profile in animal models and in
clinical trials ((Duriez et al., 1979; Julou et al., 1983).
It has been suggested that Zopiclone interacts allos-
terically with the benzodiazepine receptor complex
(Trifiletti & Snyder, 1984).
Various lines of evidence support the hypothesis
that facilitation of the postsynaptic responses to y-
aminobutyric acid (GABA) is involved in many of
the actions of the benzodiazepines (Choi et al., 1977;
Macdonald & Barker, 1978; Haefely et al., 1979;
Costa & Guidotti, 1979), the barbiturates (Nicoll et
al., 1975; Macdonald & Barker, 1979; Haefely et al.,
1979) and related central nervous system depres-
sants. In this study we evaluated the effects of six
'non-sedative' and two 'sedative' anxiolytic agents on
responses to GABA (Macdonald & Barker, 1979;
Nowak et al., 1982), and on diazepam-induced
enhancement of responses to GABA, on mouse
spinal cord and cerebral hemisphere neurones grown
in primary dissociated cell culture. In addition, the
effects of the benzodiazepine receptor antagonists Ro
15-1788 (ethyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-
4H-imidazo(1,5a)1,4)-benzodiazepine-3-carboxylate)
and CGS 8216 (2-phenylpyrazolo(4,3-c)quinolin-
3(5H)-one) on the drug-induced alteration of
responses to GABA were studied in mouse spinal
cord neurones.
Methods
Primary dissociated cell culture
Cultures of spinal cord neurones were prepared from
dissected spinal cords and attached dorsal root
ganglia from 12-14 day old foetal mice as described
previously (Ransom et al., 1977). The tissue was
minced and then mechanically dissociated by trit-
uration in Ca2+-, and Mg2+-free balanced salt solu-
tion to a suspension of single cells and small clumps.
The dissociated cells were suspended in culture
medium (90% Eagle's minimal essential medium
supplemented with 5.5 g l- 1 of glucose and 1.5 g I1-
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of NaHCO3, 5% heat-inactivated horse serum and
5% Nu-Serum II (Collaborative Research Inc., Lex-
ington, MA, U.S.A.), 325 mOsmol) and then plated
on sterile collagen-coated 35mm dishes. Each cord
produced 6 to 8 cultures. The cultures were main-
tained in an incubator with an atmosphere of 93%
room air and 7% CO2 at 350C. The
bicarbonate/CO2 buffer maintained pH at 7.4. 5-
Fluoro-2'-deoxyuridine was added to the cultures on
days 6 to 8 in order to suppress the growth of
rapidly dividing non-neuronal cells. Medium was
changed twice weekly. Cultures were maintained for
4 to 9 weeks before electrophysiological experiments.
Cerebral hemisphere cultures were prepared from
14- to 18-day gestational mice after transection of
the cervical cord. The cerebral hemispheres were dis-
sected away from the brainstem. The pieces of lateral
cortical mantle were pooled separately in Ca2 +-,
Mg2+-free balanced salt solution. After replacement
of the balanced salt solution with culture medium,
the pieces were dissociated mechanically, plated on
collagen-coated dishes (12 to 14 cultures per-
hemisphere) and maintained as described above.
Experimental procedures
Solutions All recordings were made in a Dulbecco's
phosphate buffered saline after removal of growth
medium. The recording solution, with elevated mag-
nesium ion concentration in order to suppress spon-
taneous activity, contained in mM: NaCl 137,
Na2HPO4 8.06, KCI 2.68, KH2PO4 1.47, CaCl2 1.0,
MgCl2 10 and glucose 5.6 (pH 7.3-7.4). Heavy paraf-
fin oil was applied to the surface of the bathing solu-
tion to retard evaporation.
Solutions of the tested drugs were always prepared
on the day of the experiment in the following
manner. The dry drugs were dissolved in dimethyl-
sulphoxide to form a 1 or 10mM stock solution. Ali-
quots were removed and diluted in bathing medium
to give concentrations between 1 nm and 100pM.
These final solutions contained 0.1% or less
dimethylsulphoxide.
Experimental apparatus For experiments, the
culture dish containing the bathing solution was
placed on a stage heated by a Pellitier device with
temperature regulated at 34-350C. The stage was
mounted on a Leitz inverted microscope fitted with
phase contrast optics to facilitate micropipette place-
ment (using Leitz micromanipulators) and to pen-
etrate cells under direct visual control.
Electrophysiological recordings Intracellular record-
ings were made from the somata of spinal cord
(>20,pm) and hemisphere (± 10pm) neurones with
glass micropipettes filled with 3M potassium chlo-
ride. Micropipettes with different resistances were
used for cortical (40-80MQl) and spinal cord (25-
50MQ) neurones. Use of an active bridge circuit
(Model 8100, Dagan, Inc., Minneapolis, MN, U.S.A.)
allowed simultaneous recording of membrane poten-
tial and injection of current (for steady-state polariz-
ation or periodic stimulation) with a single
micropipette. The preamplifier output signal was led
to a 6-channel polygraph, (Model 2600, Gould
Instruments, Inc., Cleveland, OH, U.S.A.) for contin-
uous recording.
Responses to GABA GABA (0.5 M, pH 3.4) was
applied iontophoretically using 5OOms duration rec-
tangular positive current pulses at 5s intervals. Ion-
tophoretic pipettes were positioned to within 2ym of
neuronal somata. The use of 3M KCl-filled micro-
pipettes shifted the chloride equilibrium potential
from about -65 mV to about -20 mV. Under these
conditions, an increase of chloride conductance
resulted in an outward chloride current (Nishi et al.,
1974), giving depolarizing responses to GABA
(Nowak et al., 1982). Responses to GABA of about
10 to 15 mV in amplitude were evoked following
membrane hyperpolarization (to -70 to -90 mV)
to avoid saturation at or near the chloride equi-
librium potential. In studies of drug effects on
responses to GABA, data were accepted only if
responses to GABA returned to control amplitude
within 5 min of removal of the drug-containing
micropipette. In studies of antagonists, data were
accepted only if the original direct effect of the
agonist returned after removal of the tested putative
antagonist.
Drug application For evaluation of drug effects on
responses to GABA, all drugs were applied by pres-
sure ejection. A blunt tipped (5-10pm) micropipette,
filled with the test solution, was positioned 15-30.pm
from the soma of the cell under study. The open end
of each pressure ejection micropipette was connected
by tight fitting polyethylene tubing to a pressure
regulator, set between 0.4 and 0.8 pounds per square
inch (psi). Pressure pulse duration, regulated by a
voltage-activated 3-way valve, was 10s. Under these
conditions, application of control solutions was vir-
tually free of effects. Pressure and position of the
pressure ejection micropipettes were adjusted to
attain a maximal drug response. We have demon-
strated previously that the concentration-
dependency of drug action determined using
pressure ejection or by superfusion are equivalent if
this experimental procedure is used (Heyer et al.,
1982). For assessment of possible antagonistic effects
at the benzodiazepine receptor, the putative antago-
nist was applied by diffusion from a large tipped (10-
20.pm) micropipette, before application by pressure
ejection of the anxiolytic drug. As a control, record-
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ing solution alone or with vehicle was applied by dif-
fusion and was without effect. To decrease leakage of
drugs into the bathing medium, the tips of the pres-
sure ejection micropipettes were kept in the oil phase
between drug application trials. They were lowered
into the aqueous phase only when drug application
was desired.
Drugs
Buspirone HCI was obtained from Bristol-Myers
Co., Evansville, Indiana, U.S.A. CGS 8216 and CGS
9896 were provided by Ciba-Geigy Corp., Summit,
New Jersey, U.SA. CL 218,872 was provided by
Lederle Laboratories, New York, NY, U.S.A. Diaze-
pam and Ro 15-1788 were obtained from Hoffman-
LaRoche, Nutley, New Jersey, U.S.A. GABA was
purchased from Sigma Chemical Company, St Louis,
Missouri, U.S.A. PK 8165 and PK 9084 were pro-
vided by Dr Sandra File, School of Pharmacy, Uni-
versity of London, U.K. ZK 91296 was provided by
A/S Ferrosan, Denmark. Zopiclone was provided by
Rhone-Poulenc Research, Vitry-sur-Seine, France.
Algebraic and statistical methods
For the different drugs at all applied concentrations,
mean values and standard deviations were calculated
for the direct effects on responses to GABA and
antagonistic effects on diazepam-induced enhance-
ment of responses to GABA. The direct effects were
expressed as % change of responses to GABA. The
antagonistic effects were expressed as % enhance-
ment of responses to GABA produced by diazepam
(100 nM) in the presence of the antagonist when com-
pared to initial enhancement produced by diazepam
(100 nM). The statistical significance of differences
between controls and drug groups was calculated by
use of Student's two-tailed t test; P < 0.05 was con-
sidered to be statistically significant.
Results
Direct effects on responses to GABA recordedfrom
spinal cord neurones
Pressure ejection of the studied drugs did not alter
resting membrane potential or conductance. Pres-
sure ejection of recording solution alone or with
vehicle (n = 10) gave non-significant enhancement
(0.8 + 1.9%) of responses to GABA. Maximal effects
of the different drugs are shown in Figure 1. Diaze-
pam (500nM) (Figure la) and zopiclone (10pM)
(Figure lb) reversibly enhanced responses to GABA.
PK 8165 at a low concentration (10nM) reversibly
enhanced responses to GABA (Figure ic), but at a
high concentration (100pM), PK 8165 reversibly
reduced responses to GABA (Figure id). CL 218,872
(10.uM) reversibly enhanced responses to GABA
(Figure le).
Effects of diazepam, zopiclone, PK 8165 and CL
218,872 on responses to GABA recorded from spinal
cord neurones were concentration-dependent (Figure
2). For diazepam, enhancement of responses to
GABA was produced at lOnm and peak enhance-
ment occurred at 500nm. A lesser enhancement was
observed at higher concentrations. For zopiclone,
enhancement was observed at 50 nm, and the
enhancement was concentration-dependent up to
1OyM. PK 8165 enhanced responses to GABA at 10,
100 and 500 nm. However, at a concentration of 1 gm,
PK 8165 was without effect. In contrast, at concen-
trations higher than 1 pM, PK 8165 reversibly
reduced responses to GABA. For CL 218,872,
enhancement was observed at 100 nm, and the
enhancement was concentration-dependent up to
1OpM.
CGS 9896, ZK 91296, PK 9084 and buspirone,
however, had no significant direct effect on responses
to GABA at concentrations ranging from 1 nm to
1O JM (Table 1).
Antagonism ofdiazepam-induced enhancement of
responses to GABA
Attempts were made to antagonize the diazepam
(100 nM)induced enhancement of the response to
GABA by the compounds that did not display a sig-
nificant direct effect on the response to GABA. These
drugs were: CGS 9896, ZK 91296, PK 9084 and
buspirone. The % increases of responses to GABA
by diazepam with and without co-application of
control or drug-containing solution were compared.
Diazepam-induced enhancement of responses to
GABA was unaffected by co-application of recording
solution alone or with vehicle (96 + 7.1% (n = 8)).
CGS 9896 (1 pM, n = 5) (Figure 3a) and ZK 91296
(1 pM, n = 5) (Figure 3b) almost completely antago-
nized diazepam-induced enhancement of responses
to GABA. However, PK 9084 (1OpM, n = 6) (Figure
3c) and buspirone (1OpM, n = 5) (Figure 3d) did not
antagonize diazepam-induced enhancement of
responses to GABA. The antagonistic effects of the
benzodiazepine receptor ligands CGS 9896 and ZK
91296 on diazepam-induced enhancement of
responses to GABA were concentration-dependent
(Figure 4). CGS 9896 antagonized diazepam-induced
enhancement of responses to GABA at a threshold
concentration of lOnM (n = 8, P < 0.001). ZK 91296
antagonized diazepam-induced enhancement of
responses to GABA at a threshold concentration of
1 nM (n = 6, P < 0.001). The estimated IC50 values
were 17 nm for CGS 9896 and 9 nm for ZK 91296.
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Pre Drug Post
a Dz 500 nM
GABA
c PK 8165 10 nM
e CL 218,872 10M1M
Pre Drug Post
b Zpc 10 FM




Figure 1 Maximal, reversible direct effects on responses to y-aminobutyric acid (GABA) on spinal cord neurones
of diazepam (Dz) 500nM (a), zopiclone (Zpc) 10pM (b), PK 8165 lOnM (c), PK 8165 100.M (d) and CL 218,872
10 yM (e). Pre shows stable responses to GABA before drug application. Drug shows the effect of each drug applied
by pressure ejection. Responses to GABA returned to control values (Post) within 2min following removal of
diazepam, PK 8165 (10nM) and CL 218,872; within 10min following removal of PK 8165 (100pM). For each drug
application illustrated, a different neurone was used. Iontophoretic GABA application (500ms) is indicated by a
horizontal bar. GABA was applied at 5s intervals. Neurones were held at -70 to -9OmV and 3M KCI-filled
recording micropipettes were used. Diazepam (500nM), zopiclone (10pM), PK 8165 (10nM) and CL 218,872 (101pM)
enhanced responses to GABA. PK 8165 (100.pM) reduced responses to GABA.
Complete antagonism of the action of diazepam was
obtained with 2pM CGS 9896 and 10pM ZK 91296.
PK 9084 and buspirone in concentrations ranging
from 1 nm to 10 pM did not antagonize the diazepam-
induced enhancement of responses to GABA (Figure
4).
Effects ofRo 15-1788 and CGS 8216 on drug-induced
enhancement ofresponses to GABA in spinal cord
neurones
The effects of Ro 15-1788, a weak partial agonist at
the benzodiazepine receptor (Skerritt & Macdonald,
1983), or CGS 8216, a weak partial inverse agonist at
the benzodiazepine receptor (DeDeyn & Macdonald,
1987) on enhancement of responses to GABA pro-
duced by diazepam, zopiclone, CL 218,872 and PK
8165 were studied. Diazepam (100nM) enhanced
responses to GABA by 43.4% (Figure 5a, Table 2).
Ro 15-1788 enhanced responses to GABA by 7.5%
at lOOnM and by 15.1% at 500 nm (Figure 5, Table
2). In the presence of Ro 15-1788 (500nM), diazepam
(100 nM)-induced enhancement of responses to
GABA was significantly reduced to 9.4% (Table 2).
Zopiclone (500nM) enhanced responses to GABA
by 43.8% (Figure Sb, Table 2). In the presence of Ro
15-1788 (100nM), the zopiclone (500nM)induced
increase of the response to GABA was significantly
reduced to 19.3% (Figure 5b, Table 2).
CL 218,872 (1 pM) enhanced responses to GABA
by 10.9% (Figure Sc, Table 2). However, CL 218,872
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Data shown are mean + s.d.
was without significant effect on the response to
GABA after diffusion of Ro 15-1788 (500 nM) (Figure
5c, Table 2). At a low concentration (10 nM) PK 8165
enhanced responses to GABA by 25.6% but had no
significant effect on responses to GABA when
applied after diffusion of Ro 15-1788 (500 nM) (Figure
5d, Table 2). At a high concentration (1OpM), PK
8165 reduced responses to GABA by 38.8% (Table
Table 2 Effects of Ro-1788 and CGS 8216 upon diazepam-, zopiclone-, CL 218,872- and PK 8165-induced changes
of responses to GABA of mouse spinal cord neurones
Number of
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Data shown are mean + s.d. The vertical line to the left of pairs of drugs indicates that the data were paired
observations. A double asterisk indicates a significant reduction of the drug-induced enhancement of GABA
responses by either Ro 15-1788 or by CGS 8216 (P < 0.05). A single asterisk indicates a significant drug-induced
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Figure 2 Concentration-dependent effects of diazepam
(A, n = 7-86), zopiclone (-, n = 5-12), PK 8165 (El,
n = 6-13) and CL 218,872 (0. n = 5) on the responses
to y-aminobutyric acid (GABA) of spinal cord neurones.
Effects are expressed as % change of the original
response to GABA. Data shown are mean and vertical
lines indicate s.d. If the s.d. is smaller than the symbol
it is not shown; s.d.'s are shown only in one
direction. n = number of cells for all concentrations
tested. *P < 0.05, **P < 0.01, ***P < 0.001 from
control responses to GABA. Diazepam, zopiclone, PK
8165 and CL 218,872 concentration-dependently
enhanced responses to GABA. At high concentrations,
PK 8165 reduced responses to GABA.
2). Application of CGS 8216 (100nM) did not signifi-
cantly alter the reduction of the responses to GABA
induced by PK 8165 (100 nM) (Table 2). CGS 8216
(100 nM) had a direct effect, reducing responses to
GABA by 9.4% (Table 2).
Effects ofCGS 9896 and ZK 91296 on cerebral
hemisphere neurones
CGS 9896 (2 gM), without having any direct effect on
responses to GABA, completely antagonized the
diazepam (100 nM)-induced enhancement of
responses to GABA on cerebral hemisphere neu-
rones (Table 3). Similar findings were obtained for
ZK 91296 (2pM) (Table 3). The simultaneous appli-
cation of diazepam (100 nM) and CGS 9896 (2/AM)
and diazepam (100 nM) and ZK 91296 (2pM) gave no
significant effect (Table 3).
No significant difference in the enhancement of
responses to GABA by diazepam (100 nM) was
observed between spinal cord neurones (41.9 + 15%,
n = 86) and cerebral hemisphere neurones
(37.3 + 11.2%, n = 10).
CGS 9896
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Figure 3 Effect of CGS 9896 1 aim (a), ZK 91296 1 JAM
(b), PK 9084 10pM (c) and buspirone (Bus) 1OpM (d) on
diazepam (Dz, 100 nM)-enhancement of responses to y-
aminobutyric acid (GABA) on spinal cord neurones.
Each row represents responses obtained on one
neurone. Column 2 shows the effect of diazepam.
Column 4 shows the direct effect of the putative antago-
nists, and column 5 shows the effects of the simulta-
neous applications of diazepam and the putative
antagonists. Columns 1, 3 and 6 show control responses
(Con), before, between and after drug applications. Ion-
tophoretic GABA-application is indicated by a horizon-
tal bar. CGS 9896 1 pM and ZK 91296 1JM almost
completely blocked diazepam (100nM)-enhancement of
responses to GABA. PK 9084 10pM and buspirone
1OpM did not antagonize responses to GABA.
Discussion
Diazepam, zopiclone and CL 218,872 enhanced
responses to GABA in a concentration-dependent
manner. Ro 15-1788, which is considered a classical
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Table 3 Direct effect and antagonism of diazepam-induced enhancement of responses to GABA by CGS 9896 and




100nM + CGS 9896 2pM
100nM + ZK 91296 2pM
Data shown are mean + s.d. The asterisk indicates a
(P < 0.05).
antagonist or weak partial agonist at the benzodia-
zepine receptor (Hunckeler et al., 1981; Skerritt &
Macdonald, 1983), antagonized these effects, suggest-
ing that the benzodiazepine receptor may be the site
of action for these anxiolytics. These findings are
consistent with previous results for diazepam
(Squires & Braestrup, 1977; Mohler & Okada, 1977),
zopiclone (Blanchard et al., 1979; 1983; Trifiletti &
Snyder, 1984) and CL 218,872 (Squires et al., 1979;
a)
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Figure 4 Effects of diazepam (100 nM)-induced
enhancement of responses to y-aminobutyric acid
(GABA) on spinal cord neurones produced by CGS
9896 (U, n = 5-8), ZK 91296 (A, n = 5-6), PK 9084 (V,
n = 4-8) and buspirone (A, n = 5) applied in concentra-
tions ranging from 1 nm to 1OpM. Effects are expressed
as remaining % of the initial enhancement of responses
to GABA induced by diazepam 100nM. Data shown are
means and vertical lines indicate s.d. Standard devi-
ations smaller than the symbols are not shown and they
are shown only in one direction. n = numbers of cells
for all concentrations tested. *P < 0.05, **P < 0.01,
***P < 0.001 from initial 100nM diazepam-induced
enhancement. CGS 9896 (IC50 = 17nM) and ZK 91296
(IC5o = 9nM) concentration-dependently antagonized
the diazepam-enhancement of responses to GABA.
However, PK 9084 and buspirone did not antagonize
















significant drug-induced change in the GABA response
Lippa et al., 1979a,b). Diazepam, with a maximal
direct effect inducing 82% enhancement of responses
to GABA, may be considered a full agonist at the
benzodiazepine receptor. This result confirms pre-
vious findings (Skerritt et al., 1984) obtained with
this methodological approach. Zopiclone, with a
maximal enhancement of 64%, also appeared to be a
full agonist at the benzodiazepine receptor. CL
218,872, with a maximal enhancement of only 20%,
was a partial agonist at the benzodiazepine receptor.
The concentration-dependent effects presented here
for zopiclone and CL 218,872 are consistent with
earlier studies using only single drug concentrations
(Skerritt & Macdonald, 1984).
PK 8165 had a mixed effect on responses to
GABA: inducing an enhancement at nm concentra-
tions and a reduction at uM concentrations.
However, pressure ejection of nm concentrations of
PK 8165, after diffusion of Ro 15-1788, was without
significant effect on responses to GABA. In contrast,
CGS 8216 (Yokoyama et al., 1982) did not antago-
nize the decrease of responses to GABA induced by
,M concentrations of PK 8165. This suggests that
PK 8165 could have another site of action in addi-
tion to the benzodiazepine receptor. While PK 8165
would act as a partial agonist at the benzodiazepine-
receptor, the inhibitory effect on responses to GABA
at JM concentrations could be mediated through
another receptor.
CGS 9896, ZK 91296, buspirone and PK 9084 in
concentrations ranging from 1 nm to 10pM, were
devoid of any significant direct effect on responses to
GABA in spinal cord neurones. CGS 9896 and ZK
91296 were free also of significant effects on
responses to GABA in cerebral hemisphere neu-
rones. In contrast, in an experiment testing the
antagonist effect on diazepam-induced enhancement
of responses to GABA, CGS 9896 and ZK 91296
acted concentration-dependently on spinal cord and
hemisphere neurones. CGS 9896 and ZK 91296,
therefore, could be classified in this system as pure
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Figure 5 Blockade by Ro 15-1788 of the direct
enhancing effect of diazepam (Dz) 1OOnM (a), zopiclone
(Zpc) 500nM (b), CL 218,872 1 pM (c) and PK 8165
1OnM (d) on responses to y-aminobutyric acid (GABA)
in spinal cord neurones. The Ro 15-1788 concentration
was 500nM (a, c and d) or lOOnM (b). Each row rep-
resents responses obtained in one neurone. Column 2
shows the direct effect of the different drugs on
responses to GABA. Column 4 shows the direct effect of
Ro 15-1788. Column 5 shows the effect of simultaneous
application of the tested drug and Ro 15-1788. Columns
1, 3 and 6 show control responses (Con) before, between
and after drug applications. lontophoretic GABA-
application is indicated by a horizontal bar. GABA was
applied every 5s. Ro 15-1788 antagonized the enhance-
ment of responses to GABA produced by diazepam, CL
218,872 and PK 8165, suggesting that the benzodiaze-
pine receptor might be the site of action for these drugs.
Macdonald, 1987). However, buspirone and PK
9084, in concentrations from 1 nm to 1O/M, remained
inactive. These findings suggest that buspirone and
PK 9084 are not benzodiazepine-receptor ligands.
This is consistent with previous results for buspirone
(Riblet et al., 1982). However, for the phenylquinol-
ines PK 9084 and PK 8165, the binding studies were
less conclusive. While shown to be benzodiazepine
receptor ligands in vitro (Gee et al., 1983; Benavides
et al., 1984 ; Keane et al., 1984), one in vivo study
(Keane et al., 1984) failed to demonstrate an affinity
for the benzodiazepine receptor.
The data presented in this study are not entirely
consistent with a unitary hypothesis that these drugs
are anxiolytic and anticonvulsant by directly
enhancing postsynaptic GABAergic inhibition. The
classification of diazepam and zopiclone (Haefely et
al., 1979; Duriez et al., 1979; Julou et al., 1983) as
full agonists and CL 218,872 (Squires et al., 1979;
Lippa et al., 1979b) and PK 8165 (Le Fur et al.,
1981) as partial agonists at the benzodiazepine
receptor is consistent with their anxiolytic action.
Administered at relatively high doses, PK 8165 was
proconvulsant (File & Simmonds, 1984). This is con-
sistent, as suggested by our findings, with an action
of this compound mediated via a receptor indepen-
dent of the benzodiazepine receptor. Several neuro-
chemical parameters, such as GABA-ratio, photo
shift, chloride shift and TBPS shift (Ehlert et al.,
1982; Karobath et al., 1983; Wood et al., 1984) are
consistent with our findings that diazepam, zopi-
clone, CL 218,872 and PK 8165 have agonist or
partial agonist actions on benzodiazepine receptors.
A discrepancy, however, was found between the lack
of direct effects on responses to GABA on mouse
spinal cord and hemisphere neurones for the
benzodiazepine-receptor ligands CGS 9896 and ZK
91296 and their anxiolytic and anticonvulsant
actions (Yokoyama et al., 1982; Petrack et al., 1983;
Petersen et al., 1984). Neurochemical studies predic-
ted a partial agonistic profile for CGS 9896 (Gee &
Yamamura, 1982) and ZK 91296 (Stephens et al.,
1984; Petersen et al., 1984). However, the benzodia-
zepine receptor antagonist effects of CGS 9896 and
ZK 91296 obtained in this study are consistent with
the behavioural findings (Brown et al., 1984; Bernard
et al., 1985; Klockgether et al., 1985). The existence
of an endogenous ligand for the benzodiazepine
receptor could explain the lack of an intrinsic effect
of CGS 9896 and ZK 91296 in our experimental
system, as opposed to behavioural and neurochem-
ical findings. The interaction of an endogenous
ligand with anxiogenic and proconvulsant activity
could explain the absence of intrinsic activity in vitro
and the observed selective agonist activity in vivo for
CGS 9896 and ZK 91296. The existence of an
endogenous anxiogenic benzodiazepine receptor
ligand has indeed been suggested (Guidotti et al.,
1982; Costa & Guidotti, 1985).
Another hypothesis for the non-sedative anxiolytic
profile of benzodiazepine receptor ligands could be
the mediation of their pharmacological effects via
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specific benzodiazepine receptor subtypes. Only for
CL 218,872 (Klepner et al., 1979; Squires et al., 1979)
and CGS 9896 (Boast et al., 1985) have different
affinities for benzodiazepine receptors in different
brain regions been proposed. For CL 218,872, its
specific interaction with a cerebellar subtype of ben-
zodiazepine receptor (Type I) has been suggested as
the basis for its selective anxiolytic effect (Klepner et
al., 1979). However, the pharmacological significance
of this receptor subtype has been challenged because
the discriminitive properties of CL 218,872 disappear
at 370C (Gee et al., 1982). Moreover, this
triazolopyridazine concentration-dependently en-
hanced responses to GABA on our non-cerebellar
neurones. A recent study, using autoradiographic
techniques, showed a significantly different affinity
for CGS 9896, less than 2 times higher, for cerebellar
cortex than for dentate gyrus (Boast et al., 1985).
Practical implications of such a small difference in
affinity seem unlikely, and moreover, the cerebellum
is a brain region not believed to be related to anxiety
but is rather involved in motor function.
Our findings failed to indicate any interaction of
PK 9084 or buspirone with the benzodiazepine
receptor complex. While PK 9084 is poorly estab-
lished as an anxioselective agent, buspirone has
been shown to be efficaceous in several clinical
trials (Goldberg & Finnerty, 1979; Goldberg &
Finnerty, 1982; Rickels et al., 1982). These results
are consistent with the conclusion that anxiety
can be treated by modification of non-GABAergic
neurotransmission, possibly including 5-
hydroxytryptaminergic, noradrenergic and dopamin-
ergic systems (for review, see: Hoehn-Saric, 1982;
Braestrup, 1982).
In conclusion, in a system testing postsynaptic
responses to GABA, two clearly sedative anxiolytics,
diazepam and zopiclone, were found to be full ben-
zodiazepine receptor agonists. CL 218,872 and PK
8165, initially thought to be non-sedative anxiolytics
but later shown to be sedative anxiolytics, were
found to be partial benzodiazepine receptor agonists.
These results are consistent with neurochemical and
behavioural findings for these compounds and sug-
gest that enhancement of GABAergic inhibition by
benzodiazepine receptor agonists is anxiolytic and
sedative. However, the non-sedative anxiolytics CGS
9896 and ZK 91296 were shown to be benzodiaze-
pine receptor antagonists. PK 9084 and buspirone
were found to be free of any interaction with the
benzodiazepine receptor complex. Our electrophysi-
ological findings together with other neurochemical
and behavioural data suggest that facilitation of
GABA-ergic neurotransmission may be sufficient,
but not necessary for anxiolysis, that benzodiazepine
receptor agonists produce sedative anxiolysis and
that benzodiazepine receptor antagonists or weak
partial agonists may produce non-sedative anx-
iolysis.
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